Effect of ribociclib on productivity losses due to breast cancer in young women in Brazil
DOI:
https://doi.org/10.11606/s1518-8787.2022056004160Keywords:
Women, Premenopause, Breast Neoplasms, therapy, Absenteeism, Workforce, economics.Abstract
OBJETIVE: To evaluate the effect of ribociclib versus endocrine therapy on productivity losses due to advanced breast cancer. METHODS: Productivity data from the MONALEESA-7 trial, obtained from the results of the application of the Work Productivity and Activity Impairment (WPAI) questionnaire on progression-free survival state (43-month follow-up), were extrapolated to the 10,936 Brazilian prevalent cases of premenopausal women with hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2-) breast cancer. Productivity loss was determined by quantifying the economic costs of workforce dropout over time in both treatment arms and by discounting the economic costs of absenteeism and presenteeism from workforce retention. A human capital approach was used. RESULTS: Net productivity gains in the ribociclib arm were estimated at USD 4,285,525.00, representing 316,609 added work hours over 43 months and a mean of 2,009 added work weeks per year. CONCLUSIONS: The phase III MONALEESA-7 trial productivity results applied to the Brazilian premenopausal prevalent cases of hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2-) breast cancer showed that treatment with ribociclib + endocrine therapy improves workforce participation compared with endocrine therapy alone in premenopausal women with hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2-) metastatic breast cancer, with potential economic gains for the Brazilian society.
References
Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, et al. Global Cancer Observatory: cancer today. Lyon (FR): International Agency for Research on Cancer; 2020 [cited 2021 Dec 13]. Available from: https://gco.iarc.fr/today
Waks AG, Winer EP. Breast cancer treatment: a review. JAMA. 2019;321(3):288-300. https://doi.org/10.1001/jama.2018.19323
DeSantis CE, Bray F, Ferlay J, Lortet-Tieulent J, Anderson BO, Jemal A. International variation in female breast cancer incidence and mortality rates. Cancer Epidemiol Biomarkers Prev. 2015;24(10):1495-506. https://doi.org/10.1158/1055-9965.EPI-15-0535
O'Shaughnessy J. Extending survival with chemotherapy in metastatic breast cancer. Oncologist. 2005;10 Suppl 3:20-9. https://doi.org/10.1634/theoncologist.10-90003-20
Axelrod D, Smith J, Kornreich D, Grinstead E, Singh B, Cangiarella J, et al. Breast cancer in young women. J Am Coll Surg. 2008;206(6):1193-203. https://doi.org/10.1016/j.jamcollsurg.2007.12.026
Partridge AH, Hughes ME, Warner ET, Ottesen RA, Wong YN, Edge SB, et al. Subtype-dependent relationship between young age at diagnosis and breast cancer survival. J Clin Oncol. 2016;34(27):3308-14. https://doi.org/10.1200/JCO.2015.65.8013
Yin W, Horblyuk R, Perkins JJ, Sison S, Smith G, Snider JT, et al. Association between breast cancer disease progression and workplace productivity in the United States. J Occup Environ Med. 2017;59(2):198-204. https://doi.org/10.1097/JOM.0000000000000936
Reyes C, Engel-Nitz NM, DaCosta Byfield S, Ravelo A, Ogale S, Bancroft T, et al. Cost of disease progression in patients with metastatic breast, lung, and colorectal cancer. Oncologist. 2019;24(9):1209-18. https://doi.org/10.1634/theoncologist.2018-0018
Dunn J, Steginga SK. Young women's experience of breast cancer: defining young and identifying concerns. Psychooncology. 2000;9(2):137-46. https://doi.org/10.1002/(sici)1099-1611(200003/04)9:2<137::aid-pon442>3.0.co;2-0
Mor V, Malin M, Allen S. Age differences in the psychosocial problems encountered by breast cancer patients. J Natl Cancer Inst Monogr. 1994;16):191-7.
Reinert T, Pellegrini R, Rol R, Werutsky G, Barrios CH. Estimation of the number of Brazilian women living with metastatic breast cancer. JCO Glob Oncol. 2020;6:307-12. https://doi.org/10.1200/JGO.19.00404
Pearce A, Sharp L, Hanly P, Barchuk A, Bray F, Cancela MC, et al. Productivity losses due to premature mortality from cancer in Brazil, Russia, India, China, and South Africa (BRICS): a population-based comparison. Cancer Epidemiol. 2018;53:27-34. https://doi.org/10.1016/j.canep.2017.12.013
Alexandre RF, Santana CF, Squiassi HB. Social and economic impact of patients with metastatic breast cancer in Brazil. Value Health. 2018;21 Suppl 1:S26. https://doi.org/10.1016/j.jval.2018.04.161
Kwapisz D. Cyclin-dependent kinase 4/6 inhibitors in breast cancer: palbociclib, ribociclib, and abemaciclib. Breast Cancer Res Treat. 2017;166(1):41-54. https://doi.org/10.1007/s10549-017-4385-3
Slamon DJ, Neven P, Chia S, Fasching PA, De Laurentiis M, Im SA, et al. Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: MONALEESA-3. J Clin Oncol. 2018;36(24):2465-72. https://doi.org/10.1200/JCO.2018.78.9909
Slamon DJ, Neven P, Chia S, Fasching PA, De Laurentiis M, Im SA, et al. Overall survival with ribociclib plus fulvestrant in advanced breast cancer. N Engl J Med. 2020;382(6):514-24. https://doi.org/10.1056/NEJMoa1911149
Im SA, Lu YS, Bardia A, Harbeck N, Colleoni M, Franke F, et al. Overall survival with ribociclib plus endocrine therapy in breast cancer. N Engl J Med. 2019;381(4):307-16. https://doi.org/10.1056/NEJMoa1903765
Tripathy D, Im SA, Colleoni M, Franke F, Bardia A, Harbeck N, et al. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial. Lancet Oncol. 2018;19(7):904-15. https://doi.org/10.1016/S1470-2045(18)30292-4
Reinert T, Pellegrini R, Barrios CH. Lack of access to CDK4/6 inhibitors for premenopausal patients with metastatic breast cancer in Brazil: estimation of the number of premature deaths. Ecancermedicalscience. 2020;14:1081. https://doi.org/10.3332/ecancer.2020.1081
Neumann PJ, Ganiats TG, Russell LB, Sanders GD, Siegel JE, editors. Cost-effectiveness in health and medicine. 2. ed. New York: Oxford University Press; 2016.
Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics. 1993;4(5):353-65. https://doi.org/10.2165/00019053-199304050-00006
Banco Central do Brasil. Conversor de moedas. Brasília, DF: BCB; 2020[cited 2021 Apr 16]. Available from: https://www.bcb.gov.br/conversao23.
Instituto Brasileiro de Geografia e Estatística. Sistema de Recuperação Automática (SIDRA). Rio de Janeiro (BR): IBGE; 2020 [cited 2021 Apr 16]. Available from: https://sidra.ibge.gov.br/pesquisa/pnadcm/tabelas
Wan Y, Gao X, Mehta S, Wang Z, Faria C, Schwartzberg L. Indirect costs associated with metastatic breast cancer. J Med Econ. 2013;16(10):1169-78. https://doi.org/10.3111/13696998.2013.826228
Ekwueme DU, Trogdon JG, Khavjou OA, Guy GP Jr. Productivity costs associated with breast cancer among survivors aged 18-44 years. Am J Prev Med. 2016;50(2):286-94. https://doi.org/10.1016/j.amepre.2015.10.006
Curteis T, Chandiwana D, Pathak P, Lanoue B, Buehler A, Pencheva R, et al. Analysis of societal costs due to work productivity loss and activity impairment from the Monaleesa-7 trial of ribociclib + endocrine therapy (ET) in premenopausal women with HR+/HER2– advanced breast cancer (ABC) in Brazil. Value Health. 2021;24 Suppl 1:S27. https://doi.org/10.1016/j.jval.2021.04.137
Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Paluch-Shimon S, et al. Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer. Ann Oncol. 2018;29(7):1541-7. https://doi.org/10.1093/annonc/mdy155
Harbeck N, Franke F, Villanueva-Vazquez R, Lu YS, Tripathy D, Chow L, et al. Health-related quality of life in premenopausal women with hormone-receptor-positive, HER2-negative advanced breast cancer treated with ribociclib plus endocrine therapy: results from a phase III randomized clinical trial (MONALEESA-7). Ther Adv Med Oncol. 2020;12:1758835920943065. https://doi.org/10.1177/1758835920943065
Cardoso F, Paluch-Shimon S, Senkus E, Curigliano G, Aapro MS, Andre F, et al. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Ann Oncol. 2020;31(12):1623-49. https://doi.org/10.1016/j.annonc.2020.09.010
Basch E. High compliance rates with patient-reported outcomes in oncology trials submitted to the US Food and Drug Administration. J Natl Cancer Inst. 2019;111(5):437-9. https://doi.org/10.1093/jnci/djy183
Published
Issue
Section
License
Copyright (c) 2022 Anna Maria Buehler, Pierre-Alexandre Dionne, David Chandiwana, Purnima Pathak, Ebuwa Igho-Osagie
This work is licensed under a Creative Commons Attribution 4.0 International License.
